ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,555,562 | -21.9% | 610,006 | -11.6% | 0.00% | -33.3% |
Q2 2023 | $21,209,001 | -17.5% | 689,948 | -3.3% | 0.01% | -14.3% |
Q1 2023 | $25,695,407 | -77.4% | 713,167 | -75.3% | 0.01% | -78.8% |
Q4 2022 | $113,935,764 | -9.4% | 2,882,990 | -7.9% | 0.03% | -17.5% |
Q3 2022 | $125,796,000 | +12.9% | 3,130,851 | +18.1% | 0.04% | +17.6% |
Q2 2022 | $111,469,000 | +318.7% | 2,651,493 | +288.0% | 0.03% | +385.7% |
Q1 2022 | $26,623,000 | +22.9% | 683,367 | +25.7% | 0.01% | +40.0% |
Q4 2021 | $21,663,000 | -4.6% | 543,599 | -13.5% | 0.01% | -16.7% |
Q3 2021 | $22,704,000 | -20.1% | 628,210 | -9.4% | 0.01% | -14.3% |
Q2 2021 | $28,427,000 | -1.7% | 693,518 | +4.7% | 0.01% | -12.5% |
Q1 2021 | $28,904,000 | +174.0% | 662,633 | +214.4% | 0.01% | +166.7% |
Q4 2020 | $10,548,000 | -69.9% | 210,735 | -74.7% | 0.00% | -75.0% |
Q3 2020 | $35,008,000 | -3.9% | 832,121 | +10.9% | 0.01% | -7.7% |
Q2 2020 | $36,413,000 | – | 750,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |